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Introduction {#pds4059-sec-0005}
============

Inhaled therapy is a key component of the management of stable Chronic Obstructive Pulmonary Disease (COPD) patients.[1](#pds4059-bib-0001){ref-type="ref"}, [2](#pds4059-bib-0002){ref-type="ref"}, [3](#pds4059-bib-0003){ref-type="ref"} Benefits in term of relieving symptoms, improving quality of life and preventing or treating exacerbations are supported by large evidence.[4](#pds4059-bib-0004){ref-type="ref"}, [5](#pds4059-bib-0005){ref-type="ref"}, [6](#pds4059-bib-0006){ref-type="ref"} However, several questions on inhaled agents are still open. Whether a particular inhalant is more beneficial than the others or whether a certain category of COPD patients is more susceptible to benefits from inhaled drugs have not been conclusively addressed.[1](#pds4059-bib-0001){ref-type="ref"}, [6](#pds4059-bib-0006){ref-type="ref"} Both the effect of inhaled corticosteroids (ICS) in reducing systemic and pulmonary inflammation and the role of combination therapy, e.g. long‐acting β2 agonists (LB) plus ICS, instead of monotherapy, are still controversial.[7](#pds4059-bib-0007){ref-type="ref"}, [8](#pds4059-bib-0008){ref-type="ref"}, [9](#pds4059-bib-0009){ref-type="ref"} The benefits over 3‐year period of follow‐up of combination therapy compared to monotherapy in two recent large clinical trials were moderate for COPD exacerbations and of borderline statistical significance for mortality.[10](#pds4059-bib-0010){ref-type="ref"}, [11](#pds4059-bib-0011){ref-type="ref"}

A critical point for the effectiveness of pharmacological treatment is adherence.[12](#pds4059-bib-0012){ref-type="ref"}, [13](#pds4059-bib-0013){ref-type="ref"} In the case of COPD, as in other common chronic diseases, patients tend to receive fewer therapy for their disease than available or prescribed.[14](#pds4059-bib-0014){ref-type="ref"}, [15](#pds4059-bib-0015){ref-type="ref"}, [16](#pds4059-bib-0016){ref-type="ref"} Relatively few studies have evaluated the impact on health outcomes of non‐adherence; different study designs and methodology make it difficult to compare results.[17](#pds4059-bib-0017){ref-type="ref"}, [18](#pds4059-bib-0018){ref-type="ref"}, [19](#pds4059-bib-0019){ref-type="ref"}

In the last decades the use of linked healthcare electronic databases has progressively increased and epidemiological studies based on them contribute to inform on adherence to drugs and their effectiveness in the real life practice.[20](#pds4059-bib-0020){ref-type="ref"}, [21](#pds4059-bib-0021){ref-type="ref"}, [22](#pds4059-bib-0022){ref-type="ref"} To our knowledge no studies have so far examined how the adherence to inhaled medications affects long‐term survival in COPD. The objective of this study is to measure the impact of regular use of inhaled drugs in people discharged after COPD exacerbation on 5‐year survival using a time‐dependent approach.

Methods {#pds4059-sec-0006}
=======

Study design, setting and data sources {#pds4059-sec-0007}
--------------------------------------

A population‐based cohort study using linked health information systems from three Italian regions (Emilia Romagna, Lazio and Lombardia, about 19 million inhabitants) was carried out. Regional health information systems were used: Hospital Information Systems (HIS) (ICD‐9‐CM codes of the International Classification of Diseases), Drug Registers (PHARM) and Mortality Registers. Details on these datasets have been described elsewhere.[23](#pds4059-bib-0023){ref-type="ref"} Drugs dispensed to patients, which are reimbursable by the National Health Service, the Italian universal coverage healthcare system, are identified by the national drug register code, accordant with the international Anatomical Therapeutic Chemical (ATC) classification.[24](#pds4059-bib-0024){ref-type="ref"} The following information was available for each prescription: patient identification number, ATC code, number of packs, number of units per pack, dosage, unit cost per pack and prescription date. In compliance with the national privacy legislation, individual data were anonymized and a unique patient identifier allowed for record linkage.

Population {#pds4059-sec-0008}
----------

From the HIS, all 45+ years old aged patients discharged after a COPD exacerbation between 1 January 2006 and 31 December 2009 were enrolled using a standardized methodology.[25](#pds4059-bib-0025){ref-type="ref"}, [26](#pds4059-bib-0026){ref-type="ref"} We selected hospital discharges with COPD as the main diagnosis (ICD 9 CM codes 490, 491, 492, 494, 496) or secondary diagnosis in presence of a main diagnosis of acute respiratory failure (ICD 9 CM codes 518.81--518.84), dyspnea (786.0), cough (786.2) or abnormal sputum (786.4). The first hospitalization which met selection criteria during the enrollment period was selected. On the basis of the Regional Drug Register, the cohort was restricted to new users, subjects with no prescription for LB and ICS in the previous 6 months before index admission, with at least a prescription of respiratory drugs during the 90 days post discharge. Details on respiratory drugs ATC codes are reported in the [Appendix](#pds4059-supitem-0001){ref-type="supplementary-material"}.

Follow‐up and outcome {#pds4059-sec-0009}
---------------------

Each patient, with at least 90 days of follow‐up and alive at the 90° day after discharge, was followed from date of discharge to the end of the study 31 December 2010 or date of death, whichever occurred first. The outcome of interest was the non accidental causes mortality (all causes mortality excluding injury and poisoning, International Classification of Disease IX revision ICD9 codes: 001‐799.9).

Drug exposure {#pds4059-sec-0010}
-------------

All prescriptions of LB and ICS dispensed during follow‐up were identified. According to standardized methodology, the number of Defined Daily Doses (DDD) available was translated into the number of days in which the patient was treated, counting one DDD per day and distributing all available DDD to the days of follow‐up.[24](#pds4059-bib-0024){ref-type="ref"}, [27](#pds4059-bib-0027){ref-type="ref"} For each day of follow‐up the time‐dependent use of inhaled drugs was calculated as the ratio between the cumulative number of days in which the drug was available, starting to discharge date and the day of follow‐up considered (proportion of days covered until that day, PDC). If a patient refilled a medication before exhausting the calculated days\' supply of previous fill, the supply in excess was redistributed the first time that the patient had days without medication. Each patient contributed to different time‐dependent drug exposures, according to the type of drug and the level of coverage.

Five categories of time‐dependent drug exposure were defined. Overall time (in days) spent in each category along the follow‐up was classified according to the following values of the PDC for LB and ICS: LB/ICS regular use: if PDC~LB~ ≥ 75% and PDC~ICS~ ≥ 75%LB/ICS occasional use: if 0 \< PDC~LB~ \< 75% or 0 \< PDC~ICS~ \< 75%LB regular use: if PDC~LB~ ≥ 75% and PDC~ICS~ = 0LB occasional use: if 0 \< PDC~LB~ \< 75% and PDC~ICS~ = 0Respiratory drugs other than LB: if PDC~LB~ = 0

In the first 90 days from the discharge, the proportion of patients in the five categories was also measured. In the literature there is no consensus on acceptable therapy adherence, with definitions varying from \>70% to \>80% in clinical research settings. We decided to set the limit for optimal adherence at ≥75%, which is between these two definitions according to previous studies.[28](#pds4059-bib-0028){ref-type="ref"}, [29](#pds4059-bib-0029){ref-type="ref"} See the [Appendix](#pds4059-supitem-0001){ref-type="supplementary-material"} for details on respiratory drugs ATC codes.

Baseline and time‐dependent covariates {#pds4059-sec-0011}
--------------------------------------

Patients were characterized at baseline according to socio‐demographic factors, diagnosis of respiratory failure (ICD9CM codes 518.81--518.84) or asthma (ICD9CM code 493), previous 2‐year COPD exacerbations (both *severe* defined as hospitalization for COPD and *moderate* defined as concomitant use of oral corticosteroids and antibacterials (ATC codes H02AB and J01), previous 6‐month use of respiratory medicaments and non‐respiratory drugs, and comorbidities.[30](#pds4059-bib-0030){ref-type="ref"} During the follow‐up, the days spent for severe or moderate COPD exacerbations or cardiovascular hospitalizations (ICD9CM codes 390--459 main diagnosis) were measured. Moreover, the regular use of cardiac therapies, antihypertensives or statins during follow‐up was measured (PDC ≥ 75%).[28](#pds4059-bib-0028){ref-type="ref"}, [29](#pds4059-bib-0029){ref-type="ref"} The year of enrollment was also introduced as potential confounder.

Details on codes for comorbidities, respiratory and non respiratory drugs are described in the [Appendix](#pds4059-supitem-0001){ref-type="supplementary-material"}.

Statistical analysis {#pds4059-sec-0012}
--------------------

The time‐dependent drug exposure starting from the 90° day post discharge was considered in the main analysis. In our model both the drug exposure and time‐dependent covariates could change value over the course of the observation period. We obtained multiple records for each individual, with each record corresponding to an interval of time during which both the drug exposure and the time‐dependent variables remain constant (counting process method). We applied the extended Cox model to estimate the hazard ratio (HR) and corresponding 95%CI of mortality associated to the different time‐dependent drug exposure, considering the period spent with LB/ICS regular use as reference. Baseline and time‐dependent covariates were taken into account through a stepwise bootstrap procedure. We perform proportional hazard model on our data using a SAS procedure called PROC PHREG, where we specified a starting and stopping time for each record.

The Cox models were replied for the subgroup of patients with previous exacerbations. A model was also run, for the whole population, to assess the effect on survival of LB regular use in comparison to respiratory drugs other than LB as reference. Cox regression survival curves were also analysed. For each time‐related drug exposure the attributable risk percentage, i.e. the percentage of deaths in the exposed group that can be attributed to the exposure (AR% = (HR − 1) / HR) was also calculated.[31](#pds4059-bib-0031){ref-type="ref"}, [32](#pds4059-bib-0032){ref-type="ref"}

Sensitivity analysis {#pds4059-sec-0013}
--------------------

We performed several sensitivity analyses. First, to evaluate the role of recent exposure we replied the analyses measuring the exposure in a mobile window of 90‐day preceding each day of follow. Second, we replied the main analyses considering all nine possible combinations of time‐dependent exposure (instead of 5) including also the PDC 0.0--75% separately for LB and ICS. Third, analyses were replied choosing a PDC cutoff point ≥ 50% instead of 75%, and, fourth, considering shorter periods of follow‐up (1 and 2 years).

Statistical analyses were performed using SAS 9.2.

Results {#pds4059-sec-0014}
=======

A total of 12 124 subjects who met the recruiting criteria were included in the statistical analyses. The flow diagram for the selection of eligible study participants is shown in Figure [1](#pds4059-fig-0001){ref-type="fig"}.

![Flow chart of inclusion and exclusion criteria](PDS-25-1295-g001){#pds4059-fig-0001}

Population characteristics {#pds4059-sec-0015}
--------------------------

The characteristics of the cohort at baseline, according to the drug exposure category measured during the first 90 days post discharge, are displayed in Table [1](#pds4059-tbl-0001){ref-type="table-wrap"}. Most patients were resident in Lombardy (47.7%), male (54.0%) and were 75--84 years old aged (38.3%). More than 40% had a respiratory failure. Ischemic diseases (19.1%), heart failure (19.6%) and cerebrovascular diseases (16.9%) were the most common comorbidities. About 70% of patients were treated with antihypertensives, 36.3% with antiplatelets, 16.6% with statins and 16.8 with anti‐diabetic drugs. In the first 90 days, the proportion of LB/ICS regular users was 22.2%, while patients treated with respiratory drugs other than LB were 26.2. In this group, the proportions of women and of very old people (85+) were higher than in the other exposure groups (53.6% and 27.7% respectively).

###### 

Patient characteristics at baseline respect the treatment measured during the first 90 days post discharge

                                     LB/ICS regular use   LB/ICS occasional use   LB regular use   LB occasional use   Respiratory drugs other than LB   Total patients
  ---------------------------------- -------------------- ----------------------- ---------------- ------------------- --------------------------------- ----------------
  Area of residence                                                                                                                                      
  Lazio                              28.9                 24.1                    28.0             25.8                33.4                              28.4
  Emilia Romagna                     22.6                 25.4                    16.4             22.3                28.8                              23.9
  Lombardia                          48.5                 50.4                    55.6             51.9                37.8                              47.7
  Gender                                                                                                                                                 
  Male                               58.7                 53.7                    60.2             54.7                46.4                              54.0
  Female                             41.3                 46.3                    39.8             45.3                53.6                              46.0
  Age                                                                                                                                                    
  45--54                             5.6                  4.7                     4.5              3.6                 2.8                               4.2
  55--64                             16.6                 12.5                    14.9             11.4                7.2                               12.2
  65--74                             30.6                 25.4                    28.1             27.5                21.4                              26.2
  75--84                             33.4                 39.1                    37.9             40.3                41.0                              38.3
  ≥85                                13.8                 18.2                    14.7             17.2                27.7                              19.0
  Year of enrollment                                                                                                                                     
  2006                               26.7                 27.0                    25.9             29.1                31.6                              28.3
  2007                               22.3                 24.8                    26.0             24.8                25.8                              24.7
  2008                               25.7                 24.5                    24.7             24.8                22.2                              24.2
  2009                               25.3                 23.8                    23.4             21.3                20.4                              22.8
  Previous exacerbations                                                                                                                                 
  Severe                             4.5                  4.9                     3.5              5.2                 5.1                               4.7
  Moderate                           7.8                  6.1                     7.3              7.6                 7.4                               7.2
  Concomitant respiratory diseases                                                                                                                       
  Asthma                             1.2                  1.5                     1.2              1.1                 1.0                               1.2
  Respiratory failure                48.5                 41.0                    42.8             42.2                40.4                              42.9
  Comorbidities                                                                                                                                          
  Diabetes                           1.7                  5.0                     1.5              4.3                 6.3                               4.0
  Ischemic disease                   14.6                 19.1                    18.2             20.5                22.5                              19.1
  Heart failure                      18.1                 19.7                    18.7             19.7                21.4                              19.6
  Liver disease                      6.9                  8.4                     8.3              9.9                 12.3                              9.3
  Cerebrovascular diseases           14.3                 15.9                    13.8             17.1                21.6                              16.9
  Depression/psychiatric diseases                                                                                                                        
  Use of drugs                                                                                                                                           
  Anti‐diabetic drugs                15.8                 15.6                    17.4             18.2                17.3                              16.8
  Antiplatelets                      32.4                 34.2                    36.6             38.3                40.1                              36.3
  Antihypertensives                  68.1                 67.0                    68.7             71.9                73.2                              69.8
  Statins                            16.8                 15.5                    17.2             18.0                16.3                              16.6
  Cardiac therapies                  11.9                 14.2                    16.1             15.6                18.8                              15.4

Drug exposure and covariates during follow‐up {#pds4059-sec-0016}
---------------------------------------------

Table [2](#pds4059-tbl-0002){ref-type="table-wrap"} shows the distribution of time‐dependent drug exposure and covariates along the follow‐up. The percentage of days spent in the different drug exposure categories varied from to 11.1% in the respiratory drugs other than LB category to 45.7% for LB/ICS occasional use. The proportion of days spent in LB/ICS regular use was 13.0%. High levels of statins and cardiac therapy regular use during the follow‐up were observed (76.3% and 78.3% of overall follow‐up days, respectively). In the LB/ICS regular use category we observed a high proportion of days with regular statins therapy (83.8% versus 78.3% in the overall) and a low proportion of days with cardiovascular hospitalizations (8.6% versus 13.9%).

###### 

Time‐dependent characteristics according to the treatment measured during the follow‐up, starting from the 90° day after discharge

                          LB/ICS regular use   LB/ICS occasional use   LB regular use   LB occasional use   Respiratory drugs other than LB   Total days
  ----------------------- -------------------- ----------------------- ---------------- ------------------- --------------------------------- ------------
  *Regular use* *of*                                                                                                                          
  Statins                 16.3                 16.6                    12.8             14.6                14.6                              15.5
  Antihypertensives       76.4                 76.0                    74.6             76.3                78.2                              76.3
  Cardiac therapies       83.8                 78.1                    77.6             77.0                76.1                              78.3
  *Proxy of gravity*                                                                                                                          
  Moderate exacerbation   31.4                 32.1                    27.1             22.2                23.2                              28.7
  Severe exacerbation     19.7                 19.6                    20.4             15.6                10.6                              17.7
  Cardiovascular hosp     8.6                  15.8                    12.7             13.8                13.6                              13.9

Note: Figures represent the proportion of days spent in the follow‐up period.

Association of drug exposure and mortality {#pds4059-sec-0017}
------------------------------------------

The associations between the drug exposure and the risk of death for the entire cohort and in the subgroup of patients with previous exacerbations are shown in Table [3](#pds4059-tbl-0003){ref-type="table-wrap"}. In comparison to the LB/ICS regular use category we found a higher risk of death for all the remaining categories. The highest risk was observed for the respiratory drugs other than LB category (HR = 1.63; 95%CI 1.43--1.87). Similar pattern of association resulted in the subgroup population (11.5% of the total) with stronger effects (HR = 2.11, 95%CI 1.47--3.03 for respiratory drugs other than LB category). The highest AR% value was found for respiratory drugs other than LB category (38.7% overall population, 52.6 % subgroup), while the absolute numbers of evitable deaths were higher in LB/ICS occasional use category (280 overall population, 82 subgroup). In the whole population, in comparison to LB/ICS occasional use, the exposure to LB regular use was associated with better survival (HR = 0.89; 95% 95% 0.79--0.99) (not shown in the table).

###### 

Association between inhaled drug use and survival (HR, 95%CI) both in the whole population under study and in the subgroup with previous exacerbations

  Cohort: *N* = 12 124, mean of follow‐up = 2.4 years, mortality rate = 11.9 per100 p. y.                                             
  ----------------------------------------------------------------------------------------- ------ ------ ------ ------ ------ ------ -----
  LB/ICS regular use                                                                        13.0   8.2    1      ---    ---    ---    ---
  LB/ICS occasional use                                                                     45.7   11.3   1.26   1.11   1.43   20.6   280
  LB regular use                                                                            12.5   9.7    1.13   0.97   1.32   11.6   39
  LB occasional use                                                                         11.1   12.7   1.34   1.16   1.56   25.5   90
  Respiratory drugs other than LB                                                           17.6   17.0   1.63   1.43   1.87   38.7   261

  People with exacerbation: *N* = 1389, mean of follow‐up = 2.3 years, mortality rate = 14.9 per100 p. y.                                             
  --------------------------------------------------------------------------------------------------------- ------ ------ ------ ------ ------ ------ -----
  LB/ICS regular use                                                                                        14.7   8.7    1      ---    ---    ---    ---
  LB/ICS occasional use                                                                                     45.2   14.4   1.65   1.17   2.32   39.4   82
  LB regular use                                                                                            13.7   11.9   1.45   0.96   2.19   30.8   17
  LB occasional use                                                                                         10.0   15.3   1.73   1.14   2.63   42.2   20
  Respiratory drugs other than LB                                                                           16.5   23.6   2.11   1.47   3.03   52.6   51

p.y. = person years

Figure [2](#pds4059-fig-0002){ref-type="fig"} shows adjusted survival probability curves considering the different exposure categories. LB/ICS regular use had the highest probability of survive. The lowest curve was found for the respiratory drugs other than LB category.

![Survival Cox curves according to the different categories of time‐dependent exposure to inhaled drugs](PDS-25-1295-g002){#pds4059-fig-0002}

Similar pattern of probability curves were found when we considered the recent exposure (Figure [3](#pds4059-fig-0003){ref-type="fig"}). Results were substantially confirmed both using different exposure classifications or cut off points and 1 or 2 year follow‐up time (data not shown).

![Survival Cox curves according to the different categories of time‐dependent exposure to inhaled drugs, measuring the exposure in a mobile window of 90‐day preceeding each day of follow‐up](PDS-25-1295-g003){#pds4059-fig-0003}

Discussion {#pds4059-sec-0018}
==========

The present large multi‐centric Italian cohort study demonstrates the fundamental role of adherence to inhaled therapy in the 5‐year survival in patients with moderate--severe COPD. The beneficial effect is higher for the combined use of LB/ICS and it is more evident in the vulnerable group with previous exacerbations.

Non‐adherence is a common problem in chronic diseases.[33](#pds4059-bib-0033){ref-type="ref"}, [34](#pds4059-bib-0034){ref-type="ref"} Studies over the past decades have shown that adherence is significantly poor in COPD even if therapies can be life sustaining.[13](#pds4059-bib-0013){ref-type="ref"}, [16](#pds4059-bib-0016){ref-type="ref"} The average adherence rates in clinical trials have been estimated to be around 70--90% among COPD patients; however, in clinical practice, these rates are only in the range of 20--60%.[14](#pds4059-bib-0014){ref-type="ref"} In our previous work on 11 452 COPD patients in Lazio region with 2‐year follow‐up on drug treatment after discharge, only 34.8% received long‐acting bronchodilators continuously.[28](#pds4059-bib-0028){ref-type="ref"} Then, under real‐life conditions non‐adherence to medication regimens may represent a significant barrier to the optimal management of COPD patients. It has been shown that discontinuation of medication may increase the frequency of exacerbations, the number of hospitalization, the number of emergency department visits and health care costs.[14](#pds4059-bib-0014){ref-type="ref"}, [15](#pds4059-bib-0015){ref-type="ref"}, [17](#pds4059-bib-0017){ref-type="ref"}, [18](#pds4059-bib-0018){ref-type="ref"}, [19](#pds4059-bib-0019){ref-type="ref"}

Based on the recent review by van Boven *et al.*, only two studies analysed the impact of non adherence on mortality over a 3‐year follow‐up period: they are both clinical trials and results have limited generalizability.[17](#pds4059-bib-0017){ref-type="ref"}, [35](#pds4059-bib-0035){ref-type="ref"}, [36](#pds4059-bib-0036){ref-type="ref"} Reasons for non‐adherence are multiple. These include factors related to the characteristics of the patient, the disease, the therapies and also the doctor--patient relationship.[12](#pds4059-bib-0012){ref-type="ref"}, [14](#pds4059-bib-0014){ref-type="ref"}, [16](#pds4059-bib-0016){ref-type="ref"}, [37](#pds4059-bib-0037){ref-type="ref"} Age, current smoking, number of respiratory drugs, polypharmacy and depression have been associated with poor adherence.[13](#pds4059-bib-0013){ref-type="ref"}, [14](#pds4059-bib-0014){ref-type="ref"}, [18](#pds4059-bib-0018){ref-type="ref"}, [38](#pds4059-bib-0038){ref-type="ref"} The real‐life contest of this study contributes to understanding the extent to which suboptimal treatment adherence may reduce the clinical benefit of the therapy and may account for many of the observed differences between the efficacy (works under experimental conditions) and the real‐world effectiveness of the COPD drug treatment.

Risk and benefits of specific inhaled medicaments in COPD have been extensively evaluated in the last decades.[7](#pds4059-bib-0007){ref-type="ref"}, [8](#pds4059-bib-0008){ref-type="ref"}, [39](#pds4059-bib-0039){ref-type="ref"} However, whether one particular treatment is more effective than another is still an open question. A recent Cochrane meta‐analysis on long acting inhalers concludes that combination inhalers (LB and ICS) positively affect quality of life and lung function while Long‐acting muscarinc antagonists and LB inhalers had similar effects, particularly at 12 months: the benefit of adding ICS to LB was higher for these outcomes in COPD patients with reduced lung function (FEV~1~ that was less than 50% predicted).[40](#pds4059-bib-0040){ref-type="ref"} On the other hand, the superiority of ICS/LB over LB alone in preventing exacerbations has not been conclusively demonstrated.[5](#pds4059-bib-0005){ref-type="ref"}, [8](#pds4059-bib-0008){ref-type="ref"} This evidence supports current guidelines indicating long‐acting beta‐agonists as key component of therapy for COPD, with regular inhaled corticosteroid therapy as an adjunct in patients experiencing frequent exacerbations.[1](#pds4059-bib-0001){ref-type="ref"}, [2](#pds4059-bib-0002){ref-type="ref"}, [3](#pds4059-bib-0003){ref-type="ref"} However, the rationale of the ICS therapy in COPD is still a matter of scientific debate.[41](#pds4059-bib-0041){ref-type="ref"}, [42](#pds4059-bib-0042){ref-type="ref"} On one hand, COPD involves both chronic inflammation of the lung, particularly in peripheral airways and parenchyma, and systemic inflammation, which may contribute to skeletal muscle weakness and cachexia and increasing propensity to cardiovascular, metabolic and bone diseases. Many inflammatory mediators have been implicated in COPD, including lipids, free radicals, cytokines, chemokines and growth factors.[41](#pds4059-bib-0041){ref-type="ref"}, [42](#pds4059-bib-0042){ref-type="ref"} Considering that systemic inflammation derives from peripheral lung inflammation, inhaled antiinflammatory treatments are expected to reduce systemic inflammation and therefore reduce or treat comorbidities. On the other hand, the inflammatory process in COPD seems largely resistant to the antiinflammatory effects of corticosteroids and their use is associated with significant morbidity from side effects.[5](#pds4059-bib-0005){ref-type="ref"}, [8](#pds4059-bib-0008){ref-type="ref"}, [41](#pds4059-bib-0041){ref-type="ref"}, [42](#pds4059-bib-0042){ref-type="ref"} In this respect, COPD guidelines recommend long‐term treatment with ICS for patients with severe and very severe COPD and frequent exacerbations that are not adequately controlled by long‐acting bronchodilators.[1](#pds4059-bib-0001){ref-type="ref"}, [2](#pds4059-bib-0002){ref-type="ref"} The Agency for Healthcare Research and Quality---National Guidelines Clearinghouse summarizes that when to use combination therapy instead of monotherapy has not been clearly established and clinicians should weigh its potential benefits and harms on a case‐by‐case basis.[43](#pds4059-bib-0043){ref-type="ref"} Our study adds to the debate on the effectiveness of inhaled drugs. We found a higher 5‐year survival associated with LB/ICS in comparison to the LB monotherapy. This finding supports the hypothesis that inhaled anti‐inflammatory drugs may promote better prognosis by reducing the risk of exacerbations and by contrasting the impact of systemic inflammation and comorbidities. The finding of an even higher effect of adding ICS to LB among those with a history of previous COPD exacerbations support the hypothesis of the beneficial role of anti‐inflammatory drugs in the complex pathophysiology of the "frequent exacerbator phenotype".[44](#pds4059-bib-0044){ref-type="ref"} In our study we assume that COPD patients discharged from hospital after an exacerbation have a moderate--severe disease and may be candidate to maintenance therapy with combined ICS/LABA according to guidelines.[28](#pds4059-bib-0028){ref-type="ref"} The fact that the regular LB use leads to a better impact on survival in comparison to the occasional LB/ICS use reinforces the importance of adherence to treatment for the health outcomes. Finally, the evidence of worst affect associated with respiratory drugs other than LB, which includes ICS monotherapy, are in keeping with current guidelines.[1](#pds4059-bib-0001){ref-type="ref"}, [2](#pds4059-bib-0002){ref-type="ref"}, [3](#pds4059-bib-0003){ref-type="ref"}

In the last decades assessing the comparative effectiveness of health interventions through observational studies has become progressively a relevant challenge.[45](#pds4059-bib-0045){ref-type="ref"}, [46](#pds4059-bib-0046){ref-type="ref"} Besides the complex methodology in comparison to highly controlled research environments, findings from this kind of studies have the potential to better inform health care decisions to improve patient outcomes. Major methodological criticisms in the comparative effectiveness research area and possible solutions have been widely discussed.[47](#pds4059-bib-0047){ref-type="ref"}, [48](#pds4059-bib-0048){ref-type="ref"} In this field of research, electronic health care databases represent a rich source of data and they have been incorporated into several governative outcomes evaluation programme in many countries (USA, UK, Italy). The use of optimal study design and statistical approach are critical elements in population‐based studies, like the present work. In order to control for time‐varying confounders when studying time‐varying exposures, marginal structural model (MSM) is considered the preferred method.[49](#pds4059-bib-0049){ref-type="ref"}, [50](#pds4059-bib-0050){ref-type="ref"} Given the complex nature of drug exposure measurements in our study, we applied a time‐dependent Cox model. In two recent literature reviews which compared conventional models and MSM when studying causal effects of time‐dependent drug use, both discrepancies in effect estimates and suboptimal reporting of the applied methodology were found.[51](#pds4059-bib-0051){ref-type="ref"}, [52](#pds4059-bib-0052){ref-type="ref"} The lack of accurate information on time‐dependent confounders and on prescription determinants remains a challenge in comparative effectiveness research and limits the interpretation of the causal relationship between drug use and outcomes.[51](#pds4059-bib-0051){ref-type="ref"}, [52](#pds4059-bib-0052){ref-type="ref"}, [53](#pds4059-bib-0053){ref-type="ref"}

The large number of people enrolled, the real‐life picture of inhaled drug use and their effectiveness, and the time‐dependent exposure measurements along the long follow‐up represent the main strengths of this study. There are some limits to be discussed. First, a major critical point is the definition of COPD patients. The discharge abstract does not contain information on clinical and functional characteristics limiting accurateness of our inclusion criteria. In a subsample of our study population we conducted a re‐abstract study on clinical records to evaluate diagnoses and severity. About 94% of reviewed cases were confirmed as being cases of COPD and with a moderate/severe level of disease, confirming previous result in our region.[54](#pds4059-bib-0054){ref-type="ref"}, [55](#pds4059-bib-0055){ref-type="ref"} Second, selection bias could be considered; however, all persons with a hospitalized COPD were enrolled with the same standardized criteria in the three regions, then we think this bias could have a limited impact in our study. Third, our pharmaceutical database does not contain information on the prescribed daily doses; therefore, the number of days in which the patient was treated was estimated on the basis of the DDDs.[24](#pds4059-bib-0024){ref-type="ref"}, [27](#pds4059-bib-0027){ref-type="ref"} Although this is a useful instrument for comparing the results from different studies, misclassification of drug utilization may have occurred.[24](#pds4059-bib-0024){ref-type="ref"}, [56](#pds4059-bib-0056){ref-type="ref"} Although this is well‐known methodology, we cannot exclude misclassification of drug utilization. It is to note of our source of data refers to prescription and we do not know the exact level of intake by the patients. However this is a known limitation of studies like that and it produces limited distortion in the estimates of association.[57](#pds4059-bib-0057){ref-type="ref"} Fourth, the choice of the measures of adherence and the cut‐off points was based on literature and our previous work.[28](#pds4059-bib-0028){ref-type="ref"}, [29](#pds4059-bib-0029){ref-type="ref"} Results from sensitivity analyses using different exposure measurements and classifications and shorter follow‐up confirm the main findings and support the validity of the study. Fifth, in our study, the HRs, the AR % and the number of preventable deaths were derived from Cox proportional hazard models in which a large number of potential confounders, both fixed and time‐dependent, were included. However, when quantifying the effect of an exposure by estimating the number of cases that were caused by it, it is necessary to take into account the mechanisms that produce effects. The observation of an exposed case does not reveal the mechanism that caused the case; people who have the exposure can develop the disease from a mechanism that does not include the exposure.[32](#pds4059-bib-0032){ref-type="ref"} In our study, besides the number of confounders included in the analysis, we cannot exclude the role of unknown factors we were not able to measure. To address this issue, one should consider that better compliance alone might be associated with improved outcomes (e.g. also in placebo groups of trials). However, only randomization can completely rule out residual confounding.

Our study shows the effectiveness of the regular use of combined LB/ICS on long‐term survival. Being regular users of LB is associated to better survival in comparison to suboptimal combined LB/ICS treatment. Considering that this study is based on patients discharged from hospitals, relevant impact on health outcomes of adherence to optimal treatment with inhalers could be expected in the overall COPD population.
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